Sign In
Buy CRMD
$8.23
+0.0600 (+0.734%)
At Close: Jun 03, 2026
Phocas Financial Corp. Takes $1.99 Million Position in CorMedix Inc $CRMD
06:44am, Monday, 06'th Apr 2026
Phocas Financial Corp. bought a new stake in shares of CorMedix Inc (NASDAQ: CRMD) during the undefined quarter, according to its most recent filing with the SEC. The firm bought 171,087 shares of the
Assenagon Asset Management S.A. Increases Stock Holdings in CorMedix Inc $CRMD
03:18am, Monday, 30'th Mar 2026
Assenagon Asset Management S.A. increased its stake in shares of CorMedix Inc (NASDAQ: CRMD) by 35.0% during the undefined quarter, according to the company in its most recent filing with the SEC. The
CorMedix CEO touts Melinta pivot, DefenCath TDAPA transition and Q2 REZZAYO Phase 3 data at Leerink
02:02am, Monday, 16'th Mar 2026
CorMedix (NASDAQ: CRMD) Chief Executive Officer Joseph Todisco told attendees at the Leerink Global Healthcare Conference that the company has undergone a significant shift over the last year, moving
CorMedix Touts Q2 REZZAYO Data, Melinta Integration and DefenCath Reimbursement Shift at Conference
02:02am, Monday, 16'th Mar 2026
CorMedix (NASDAQ: CRMD) executives used a presentation at the Citizens Life Sciences Conference to outline the company's focus on expanding its pipeline while integrating the recently acquired Melinta
CorMedix Q4 Earnings Call Highlights
04:49am, Saturday, 07'th Mar 2026
CorMedix (NASDAQ: CRMD) executives said 2025 was a "transformational" year, highlighted by DefenCath reaching peak sales of "just under $260 million," the acquisition of Melinta Therapeutics, and the
CorMedix Inc. (CRMD) Q4 2025 Earnings Call Transcript
02:55pm, Thursday, 05'th Mar 2026
CorMedix Inc. (CRMD) Q4 2025 Earnings Call Transcript
CorMedix (CRMD) Lags Q4 Earnings Estimates
09:50am, Thursday, 05'th Mar 2026
CorMedix (CRMD) came out with quarterly earnings of $0.61 per share, missing the Zacks Consensus Estimate of $0.86 per share. This compares to earnings of $0.22 per share a year ago.
CorMedix Inc. Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
07:30am, Thursday, 05'th Mar 2026
‒ Q4 2025 Net Revenue of $128.6 million ‒ ‒ Pro Forma Full Year 2025 Net Revenue of $401.3 million ‒ ‒ Q4 2025 Net Income of $14.0 million; Adjusted EBITDA of $77.2 million ‒ ‒ Confe
CorMedix Inc. to Report Fourth Quarter and Full Year 2025 Financial Results and Provide a Corporate Update on March 5, 2026
08:30am, Monday, 02'nd Mar 2026
BERKELEY HEIGHTS, N.J., March 02, 2026 (GLOBE NEWSWIRE) -- CorMedix Therapeutics (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-thr
CRMD vs. TBPH: Which Small-Cap Biotech Stock Is the Better Bet?
09:06am, Tuesday, 24'th Feb 2026
CorMedix and Theravance take sharply different routes to small-cap biotech growth - one fueled by sales traction, the other by pipeline promise.
Should Investors Buy, Sell or Hold CRMD Stock Ahead of Q4 Earnings?
11:45am, Monday, 23'rd Feb 2026
CorMedix heads into Q4 earnings with DefenCath sales, Melinta product contributions, and its muted 2026 guidance firmly in focus.
Principal Financial Group Inc. Invests $1.01 Million in CorMedix Inc $CRMD
03:26am, Thursday, 19'th Feb 2026
Principal Financial Group Inc. bought a new stake in shares of CorMedix Inc (NASDAQ: CRMD) in the undefined quarter, according to its most recent filing with the SEC. The institutional investor bought
CorMedix Down 27% in 3 Months: Is It Time to Sell the Stock?
11:30am, Tuesday, 17'th Feb 2026
CRMD stock sinks 27% in 3 months as its bearish 2026 outlook for DefenCath clouds near-term growth, raising investor concern.
CorMedix Inc. (CRMD) Analyst/Investor Day Transcript
02:37am, Saturday, 14'th Feb 2026
CorMedix Inc. (CRMD) Analyst/Investor Day Transcript
CorMedix to Participate in Upcoming Investor Conferences
08:30am, Thursday, 12'th Feb 2026
BERKELEY HEIGHTS, N.J., Feb. 12, 2026 (GLOBE NEWSWIRE) -- CorMedix Therapeutics (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-thre
